Arrodux4 now SRP1001 works
To my fellow FSHDers, some good news—unless someone else has already posted it.
The main link worth reading:
https://investorrelations.sarepta.com/static-files/7de668c5-4a60-440c-8dd9-22884fd57703
It absolutely blows Avidity’s intracellular concentration and DUX4 reduction results out of the water.
Phase 2 enrolment is expected to begin in late 2026 (october) or early 2027:
https://www.sarepta.com/community-letter-update-fshd1-clinical-development-program